SLNO - Soleno Therapeutics And Acadia Pharmaceuticals: Hope For Prader-Willi Families
2024-01-22 22:42:14 ET
Summary
- ACADIA Pharmaceuticals and Soleno Therapeutics are both conducting late-stage trials for the treatment of Prader-Willi Syndrome.
- PWS is a rare disease characterized by various physical and developmental challenges.
- Acadia is an established commercial stage company, while Soleno is a clinical stage company focused on PWS.
I have followed and chronicled the ups and downs of ACADIA Pharmaceuticals ( ACAD ) since 07/2017's "Acadia: Order For Central Nervous Systems In Need". My most recent Acadia article was "Acadia Pharmaceuticals: Nuplazid's (Pimavanserin) Last Hurrah" ("Hurrah").
As for Soleno Therapeutics ( SLNO ) this is my very first analysis of it. The indication that ties these two together in this article is their respective late stage trials in treatment of Prader-Willi Syndrome [PWS]....
Soleno Therapeutics And Acadia Pharmaceuticals: Hope For Prader-Willi Families